Generated by AI
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation. Kiniksa serves patients and healthcare providers in the United States, the United Kingdom, and other international markets, with emphasis on specialized treatments for cardiovascular and autoimmune disorders. The company’s role in the healthcare sector is defined by its concentration on targeted biologic medicines that address serious conditions with limited treatment options. Headquartered in London, Kiniksa Pharmaceuticals International, plc operates as a commercial-stage biopharmaceutical business within the global specialty drug market.
Website105 Piccadilly
London, W1J 7NJ
United Kingdom
The latest articles about KNSA.
LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kini
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Investors talking about KNSA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.